The move follows an administration push for cuts to the NSF and raises concerns in the scientific community that it could ...
18h
Milestone for Crispr: First-of-Its-Kind Gene Editing Treatment Successfully Passes Clinical Trial
Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...
Intellia Therapeutics (NTLA) shares charged up on April 27 after the company announced landmark Phase 3 results for its ...
By Kunal Das and Kamal Choudhury April 27 (Reuters) - Intellia Therapeutics said on Monday its experimental gene-editing therapy reduced the frequency of swelling attacks in patients with a rare ...
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...
For most of their lives, plants get their energy from photosynthesis. But during the seed to seedling stage, when they can't ...
The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial ...
With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...
Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...
Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results